Respiratory Complications of Plasmodium vivax Malaria: Systematic Review and Meta-Analysis

Fernando Val, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado
Kim Machado, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado
Lisiane Barbosa, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado
Jorge Salinas, Emory University
Andre Machado Siqueira, Fundacao Oswaldo Cruz
Maria Gracas Costa Alecrim, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado
Hernando del Portillo, Barcelona Institute for Global Health
Quique Bassat, Barcelona Institute for Global Health
Wuelton Marcelo Monteiro, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado
Marcus Vinicus Guimaraes Lacerda, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado

Journal Title: American Journal of Tropical Medicine and Hygiene
Volume: Volume 97, Number 3
Publisher: American Society of Tropical Medicine and Hygiene | 2017-01-01, Pages 733-743
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.4269/ajtmh.17-0131
Permanent URL: https://pid.emory.edu/ark:/25593/tdgmk

Final published version: http://dx.doi.org/10.4269/ajtmh.17-0131

Copyright information:
© The American Society of Tropical Medicine and Hygiene

Accessed October 17, 2020 2:32 AM EDT
Respiratory Complications of Plasmodium vivax Malaria: Systematic Review and Meta-Analysis

Fernando Val,1,2 Kim Machado,1,2 Lisiane Barbosa,2 Jorge Luis Salinas,3 André Machado Siqueira,4 Maria Graças Costa Alecrim,1,2 Hernando del Portillo,5 Quique Bassat,6 Wuelton Marcelo Monteiro,1,2 and Marcus Vinicius Guimarães Lacerda1,2,7

1 Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Amazonas, Brazil; 2 Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil; 3 Emory University School of Medicine, Atlanta, Georgia; 4 Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil; 5 Barcelona Institute for Global Health (ISGlobal) and ICREA and Institut d’Investigacions Germans Trias i Pujol (IGTP), Badalona, Spain; 6 Barcelona Institute for Global Health (ISGlobal) and ICREA, Badalona, Spain; 7 Instituto de Pesquisas Leôndidas and Maria Deane, Fundação Oswaldo Cruz, Manaus, Amazonas, Brazil

Abstract. Malaria, a major global public health problem, is mainly caused by Plasmodium falciparum and Plasmodium vivax, and is responsible for nearly half a million deaths annually. Although P. vivax malaria was not believed to cause severe disease, recent robust studies have proved otherwise. However, the clinical spectrum and pathogenesis of severe vivax malaria and, especially, its respiratory complications remain poorly understood. A systematic search for articles reporting respiratory complications associated with vivax malaria was performed in Lilacs, Cochrane, Scielo, Web of Science, and Medline databases irrespective of publication date. Prevalence of acute respiratory distress syndrome (ARDS) and associated mortality among vivax patients were calculated from cross-sectional and longitudinal studies, whereas factors associated with mortality were calculated from data pooled from case reports and series of cases. A total of 101 studies were included (49 cross-sectional or longitudinal and 52 case reports or series of cases). Prevalence of ARDS was 2.8% and 2.2% in children and adults, respectively, with nearly 50% mortality. Moreover, female sex (P = 0.013), having any comorbidity (P = 0.036), lower body temperature (P = 0.032), lower hemoglobin (P = 0.043), and oxygen saturation (P = 0.053) values were significantly associated with mortality. Plasmodium vivax malaria respiratory complications included ARDS and were associated with high mortality. Demographics and clinical characteristics upon presentation to hospital were associated with mortality among patients with respiratory complications in vivax malaria. This study reaffirms the evidence of severe and fatal complications of P. vivax malaria and its associated respiratory complications.

INTRODUCTION

Malaria is a major global public health problem with 3.4 billion people at risk over 91 endemic countries and territories in 2016.1 Despite improvements since 2000, malaria still imposes a great burden causing 212 million cases and 429,000 deaths in 2015.1 Of five Plasmodium species causing human malaria, Plasmodium vivax is the most widespread2 with great impact in endemic regions,3 and responsible for 41% of malaria-related cases, 0.7% of world malaria deaths, and 9% of malaria deaths outside Africa.1 The World Health Organization (WHO) estimated 8.5 million cases and 3,100 deaths from vivax malaria in 2015.1

Although falciparum malaria is definitely considered more lethal, it is now evident that P. vivax infection also causes severe disease and death.4,5 The clinical spectrum of vivax malaria ranges from asymptomatic infection to severe disease.6,7 Recognizing and managing malaria respiratory complications is challenging for health-care practitioners in endemic areas. The spectrum ranges from cough and acute breathlessness, to pulmonary edema, acute respiratory distress syndrome (ARDS), and death even after malaria treatment initiation.8–13 In a recent review of severe falciparum malaria cases, respiratory distress (RD) was reported in 25% of adults and 40% in children, whereas ARDS was found in up to 25% of adults; associated mortality was nearly 50% with intensive care and 80% without ventilator support.14 Recently, respiratory complications have also been reported in nonfalciparum malaria including P. vivax.15–22

The underlying pathogenic mechanisms of respiratory complications associated with vivax malaria are not entirely understood.23 Robust evidence for lung impairment in P. vivax malaria has only emerged recently. Therefore, the primary objective of this review was to describe the prevalence and mortality of respiratory complications in vivax malaria. Secondary objectives were to describe geographical variation, clinical characteristics, risk factors for mortality, and associated pathogenesis.

METHODS

A systematic review addressing respiratory complications caused by P. vivax malaria was conducted using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.24,25 We systematically identified studies reporting respiratory complications (Table 1). The last search was performed in November 2016. Additional studies were obtained through search of references. No date or language restrictions were applied. All study designs with primary data were included.

We reviewed titles and abstracts to confirm they included data on malaria infection, human population, P. vivax mono-infection, and respiratory complications. Included studies were assessed for eligibility through full-text review and excluded when reporting inconclusive Plasmodium species, non-respiratory complications, or if these were secondary to other organ impairment. All reviews were conducted by two independent reviewers (Fernando Val and Kim Machado) and disagreements were resolved by consensus.
Measures and definitions. In cross-sectional and longitudinal studies, the following data were retrieved: sample size, number of severe and pulmonary malaria (PM, defined as any evidence of respiratory complication detected by any clinical and/or laboratory alteration), and mortality. In this study, pediatric population referred to individuals under 17 years of age, and adult population to those 18 years or older. The type of respiratory complication was used exactly as reported in the original study. Case reports and series of cases were used to describe demographic, clinical, laboratory, and disease characteristics and any histopathological findings. Nine additional cases with vivax PM from Manaus, Brazil, were included. The following definitions were used: presence of comorbidities and other alterations were any reported at medical examination; altered clinical status at baseline was any clinical alteration at admission; presence of signs and symptoms in previous days to hospital presentation; any disease symptom present before admission; time of RD onset was defined by time between admission and RD; timing of RD onset and start of antimalarial treatment; whether RD started before or after antimalarial treatment initiation; noninvasive oxygen supplementation was any oxygen support excluding those via intubation.

Statistical analyses. To compare PM proportion among pediatric and adult populations, type of respiratory complication, and age group data were pooled, categorized (1—prevalence of PM among all cases, 2—prevalence of PM among severe cases, and 3—mortality due to PM), and compared. Data from case reports were described as mean and one standard deviation or median and interquartile range and tested according to normality. Independent t tests, Wilcoxon Mann–Whitney (frequency of children versus adults; survivors versus non-survivors) or χ² test were applied. Significance was set as P < 0.05. Analyses were performed using STATA version 12.1 (Stata Corp., College Station, TX).

RESULTS

The original search returned 608 studies. After duplicate removal and review of titles and abstracts, 84 studies were included. After inclusion of 17 additional papers, a total of 101 studies were analyzed and separated in two major groups, the first containing 49 studies (cross-sectional or longitudinal studies) and the second 52 case reports and series of cases (Figure 1).

Study characteristics. Longitudinal and cross-sectional studies: Data were extracted from 49 studies reporting respiratory complications in P. vivax malaria [26–74] (Supplemental Table 1). There was heterogeneity in the terminology used to describe respiratory complications. A total of 29 studies (59.1%) reported ARDS, 10 (20.4%) RD, two (4%) respiratory failure, one (2%) lung injury, one (2%) pulmonary edema, one (2%) acute respiratory distress, and the remaining five (10.2%) a combination between ARDS, RD, acute lung injury, and pulmonary edema. A total of 42 studies (85.7%) adopted WHO definitions for PM, whereas the remaining used general or country-specific definitions or did not report the adopted definition (Table 2).

Case reports and series of cases: A total of 67 cases were analyzed (58 cases from included case reports and series of cases, [11–13,58,99,75–118] and additional nine cases from Manaus, Brazil). The earliest identified report was from 1993 (Figure 2). Cases were predominantly from India (Table 3) and diagnosed mainly by peripheral blood films (Table 4).

Respiratory complications frequency and mortality. Overall, 450,115 patients were pooled from longitudinal and cross-sectional studies; 5,448 with severe disease, 453 developing PM, and 74 deaths. The overall prevalence of respiratory complications was 0.1% among patients and 8.3% among severe cases, with a mortality of 16.3% (Supplemental Table 1).

According to WHO-defined regions, the highest frequency of PM (8.7%) occurred in southeast Asia. More details are found in Supplemental Table 2.

Frequency of ARDS was 2.4% in 23 studies, mostly in hospitalized patients (N = 3,574 patients) (Table 5). A total of 1,156 developed severe malaria, 85 presenting ARDS (7.3%). Mortality among patients with ARDS was 49.5%. In children, ARDS frequency was 2.8% (48.3% mortality). In adults, 2.2% presented ARDS (50% mortality). There was no statistical difference in ARDS prevalence (P = 0.315) and mortality (P = 0.787) between children and adults.

On the other hand, among patients who died due to vivax-associated respiratory complications, pulmonary malaria was present in 52.9%, in a series of 17 autopsies cases, the best report was from 1993 (Figure 2). In Papua, 26 out of 65 patients with P. vivax infection who died had any respiratory complication, that is, 40%, similar to the autopsy series. [119]

Clinical and epidemiological case characteristics. Among individual case reports, there was a slight predominance of male sex (57.6%). Most cases (73.1%) aged between 19 and 49 years. Comorbidities and other relevant medical conditions were described in 33.3%, i.e., hypertension, diabetes, hypercholesterolaemia, β-thalassaemia, parasites coinfections, previous histoplasmosis, previous myocardial infarction, malignant vasovagal syndrome, occasional tobacco use, and chronic obstructive pulmonary disease. Two patients were pregnant. Most patients presented with respiratory complications on hospital admission (55.2%), predominantly increased respiratory rate (75%) and heart rate

<table>
<thead>
<tr>
<th>Database</th>
<th>Search strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lilacs</td>
<td>(vivax AND pulmonary) OR (vivax AND respiratory) OR (vivax AND ARDS)</td>
</tr>
<tr>
<td>Cochrane</td>
<td>(Plasmodium vivax malaria AND pulmonary) OR (Plasmodium vivax malaria AND respiratory) OR (Plasmodium vivax malaria AND pulmonary oedema) OR (Plasmodium vivax malaria AND ARDS) OR (Plasmodium vivax malaria AND human ards)</td>
</tr>
<tr>
<td>Scielo</td>
<td>(Plasmodium vivax malaria (MeSH Term) AND pulmonary; Plasmodium vivax malaria (MeSH Term) AND respiratory; Plasmodium vivax malaria (MeSH Term) AND respiratory distress; Plasmodium vivax malaria (MeSH Term) AND pulmonary oedema; malaria AND ards; (Plasmodium vivax malaria [MeSH Terms]) AND human ards (MeSH Terms))</td>
</tr>
<tr>
<td>Web of Science</td>
<td>(Plasmodium vivax malaria AND pulmonary) OR (Plasmodium vivax malaria AND respiratory) OR (Plasmodium vivax malaria AND pulmonary oedema) OR (Plasmodium vivax malaria AND ARDS) OR (Plasmodium vivax malaria AND human ards)</td>
</tr>
<tr>
<td>Medline/PubMed</td>
<td>Plasmodium vivax malaria (MeSH Term) AND pulmonary; Plasmodium vivax malaria (MeSH Term) AND respiratory; Plasmodium vivax malaria (MeSH Term) AND respiratory distress; Plasmodium vivax malaria (MeSH Term) AND pulmonary oedema; malaria AND ards; (Plasmodium vivax malaria [MeSH Terms]) AND human ards (MeSH Terms)</td>
</tr>
</tbody>
</table>
(62.2%), and/or reduced pulse oximetry (46.6%). Anemia (81.8%), thrombocytopenia (91.6%), and elevated liver enzymes (55.1%) were also observed. Median parasite density was 14,780 per μL (Table 6).

Vivax malaria diagnosis was performed in the first day in almost all cases. RD started before hospitalization in 27.1% and occurred after the start of antimalarial treatment in 62.7%. Parasite clearance occurred after RD onset in 87.2%. Median of hospitalization was 13 days (Table 6).

Almost all patients were reported to have received supplementary oxygen (98.2%): 33.9% were managed by non-invasive strategies, with positive pressure ventilation strategies in some cases. In the remaining 66.1%, invasive strategies were necessary with some reporting use of low-tidal volumes, moderate levels of positive end expiratory pressure, and other protective ventilation strategies. Other approaches adopted were prone positioning and extracorporeal membrane oxygenation (Table 6).

Survivors and non-survivors. Female sex was associated with higher mortality \((P = 0.013)\). One female was pregnant. Comorbidities \((P = 0.038)\) and respiratory complications at admission \((P = 0.031)\) were more frequent among deceased patients. Body temperature \((P = 0.032)\), hemoglobin level \((P = 0.043)\), and oxygen saturation \((P = 0.053)\) were lower at hospital presentation among non-survivors. Non-survivors were kept on oxygen support for less time \((P = 0.028)\), with a great predominance of cases being reported to use invasive oxygen delivery strategies \((P = 0.076)\). Moreover, these patients had shorter hospitalizations \((P = 0.007)\) (Table 6).

**Histopathological and functional studies.** Few studies provided histopathological findings. A study published in 1993 revealed bronchiolitis obliterans organizing pneumonia.\(^{103}\) Further studies reported the presence of monocytes, lymphocytes, and neutrophils in pulmonary microvasculature along with phagocytosed pigment and diffuse alveolar damage\(^{110,115}\) accompanied by hyaline membrane formation.\(^{13}\) Severe alveolar edema and congestion with infiltrates containing mononuclear cells and suggestive images of adhesion of \textit{Plasmodium}-infected red cells to lung microvasculature were reported in an autopsy series.\(^{120}\) Functional studies reported gas flow impairments with reduction of vascular component at presentation and improvement by day 7, and also with alveolar-capillary membrane component decreased at presentation with progressive deterioration after 14 days from treatment in severe vivax malaria.\(^{121}\) Of note, a case without any clinical or laboratory evidence of vivax induced respiratory complications was reported in 1989 and showed a reversible diffuse lung uptake of technetium-99m sulfur colloid during acute and recovery periods, which could indicate, according to the authors, a malaria-induced increase in lung macrophages.\(^{122}\)

**DISCUSSION**

Pulmonary edema and ARDS are features of severe falciparum malaria adopted since 1990,\(^{123}\) and have been used...
<table>
<thead>
<tr>
<th>Author, year (reference)</th>
<th>Name</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bernard, 1994\textsuperscript{146}</td>
<td>AECC definition</td>
<td>Timing: Acute onset; Radiograph: Bilateral infiltrates (frontal chest radiograph); PAWP: $\leq 18$ mmHg or no clinical evidence of left atrial hypertension; Oxygenation: \textit{ALI criteria:} $\text{PaO}_2/\text{FiO}_2 \leq 300$, \textit{ARDS criteria:} $\text{PaO}_2/\text{FiO}_2 \leq 200$ (regardless of PEEP level)</td>
</tr>
<tr>
<td>The ARDS Definition Task Force, 2012\textsuperscript{127}</td>
<td>Berlin definition</td>
<td>Timing: Within 1 week of a known clinical insult or new or worsening respiratory symptoms; Chest imaging: Bilateral opacities—not fully explained by effusions, lobar/lung collapse, or nodules; Origin of edema: Respiratory failure not fully explained by cardiac failure or fluid overload\textsuperscript{†}; Oxygenation: Mild (200 mmHg &lt; $\text{PaO}_2/\text{FiO}_2 \leq 300$ mmHg); Moderate (100 mmHg &lt; $\text{PaO}_2/\text{FiO}_2 \leq 200$ mmHg); Severe ($\text{PaO}_2/\text{FiO}_2 \leq 100$ mmHg). Obs.: PEEP or CPAP $\geq 5$ cm H$_2$O (Mild) or PEEP $\geq 5$ cm H$_2$O (moderate and severe)</td>
</tr>
<tr>
<td>Riviello, 2016\textsuperscript{128}</td>
<td>Kibali modification</td>
<td>Timing: Within 1 week of a known clinical insult or new or worsening respiratory symptoms; Imaging: Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules by chest radiograph or ultrasound; PEEP requirement: No PEEP requirement, consistent with AECC definition; Origin of edema: respiratory failure not fully explained by cardiac failure or fluid overload\textsuperscript{†}; Oxygenation: $\text{SpO}_2/\text{FiO}_2 \leq 315$</td>
</tr>
<tr>
<td>WHO definitions and clinical features of respiratory impairment in malaria</td>
<td>Severe and complicated malaria</td>
<td>Pulmonary edema: Sudden development after one or two days of treatment in adults. Evidence may include fluid overload, raised central venous or pulmonary artery wedge pressures and grossly positive fluid balance. It may also develop suddenly after delivery in pregnant women in positive fluid balance. Risk factors include hyperparasitemia, renal failure, pregnancy. Metabolic acidosis and hypoglycemia may be associated</td>
</tr>
<tr>
<td>WHO, 1990\textsuperscript{123}</td>
<td>Severe falciparum malaria</td>
<td>RD (associated acidosis): Raised RR, deep breathing and increased depth of respiration accompanied by a degree of intercostal indrawing (lower chest wall); pulmonary edema: later in course of disease with acute development. Presence of increased RR and chest x-ray evidencing pulmonary edema. PAWP may be normal.</td>
</tr>
<tr>
<td>WHO, 2000\textsuperscript{124}</td>
<td>Severe malaria</td>
<td>RD (acidosis)—Clinical features: Deep breathing, with indrawing of the bony structures of the lower chest wall, in the absence of localizing chest signs, suggests metabolic acidosis. Indrawing of the intercostal spaces alone is a less useful sign; pulmonary edema – Clinical features: increase in the respiratory rate, preceded by chest signs (radiograph resembling ARDS), reduced PaO$_2$. Hypoxia may cause convulsions and consciousness</td>
</tr>
</tbody>
</table>

(continued)
also to define severe vivax malaria afterward. In this study, we proposed to estimate prevalence and mortality of respiratory complications in vivax malaria along with risk factors associated to death. The analysis of longitudinal and cross-sectional studies showed that respiratory complications and ARDS occur in lower frequencies in vivax malaria, both in children and adults, but with a mortality resembling falciparum disease. Female gender, presence of comorbidities, and respiratory complications at hospital admission along with lower hemoglobin and body temperature measurements were associated with death.

Most of the studies were published before 2012 and used previous WHO definitions for respiratory complications.124,125 Bedside clinical classification of RD has two degrees according to WHO with similar clinical features among children and adults.126 Lung edema is a criterion for severe falciparum disease and is defined through clinical and radiological criteria.126 ARDS, with a definition update in 2012,127 was also commonly reported in studies analyzed in this review. Despite advances in ARDS diagnosis and treatment, most malaria-endemic areas are resource-poor settings. Therefore, misdiagnosis, underreporting, and incorrect management may occur. A more inclusive ARDS diagnostic tool, which withdraws positive end-expiratory pressure requirements and keeps only imaging and a single oxygen saturation cutoff value, has been developed, and despite lacking validation, it seems a promising epidemiological tool for ARDS.128

The presence of comorbidities and altered clinical and laboratory parameters at hospital admission may serve as early indicators of disease severity and risk of death. Underlying diseases, such as hypertension and diabetes, may indicate a greater hemodynamic compromise with an exacerbated inflammatory profile.129 These might contribute to vivax mortality through disturbances in cytokine production, endothelial activation, altered thrombostasis, and further deterioration, and the patient may die within a few hours. In pregnant, it may develop suddenly and unexpectedly several days after admission or may occur immediately after childbirth.

Table 2

<table>
<thead>
<tr>
<th>Author, year (reference)</th>
<th>Name</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO, 2014126</td>
<td>Severe malaria</td>
<td>Bedside clinical classification of severe malaria (children and adults). RD (acidotic breathing): Mild—sustained nasal flaring and/or mild intercostal indrawing; Severe—either marked indrawing of the bony structure of the lower chest wall or deep (acidotic) breathing. Adults—Pulmonary edema: Radiologically confirmed, or oxygen saturation &lt; 92% on room air with a respiratory rate &gt; 30/minutes, often with chest indrawing and crepitation on auscultation; Acidosis: Severe acidosis manifests clinically as RD—rapid, deep, and labored breathing</td>
</tr>
</tbody>
</table>

Table 3

<table>
<thead>
<tr>
<th>Country of publication</th>
<th>No. of cases (% of total)</th>
<th>No. of deaths (% of deaths)</th>
</tr>
</thead>
<tbody>
<tr>
<td>India</td>
<td>21 (31.4)</td>
<td>4 (33.3)</td>
</tr>
<tr>
<td>United States</td>
<td>10 (15)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Brazil</td>
<td>10 (15)</td>
<td>3 (25)</td>
</tr>
<tr>
<td>England</td>
<td>5 (7.6)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Colombia</td>
<td>4 (5.9)</td>
<td>3 (25)</td>
</tr>
<tr>
<td>Greece</td>
<td>2 (2.9)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Pakistan</td>
<td>2 (2.9)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Spain</td>
<td>2 (2.9)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Thailand</td>
<td>2 (2.9)</td>
<td>1 (8.3)</td>
</tr>
<tr>
<td>Germany</td>
<td>1 (1.5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Italy</td>
<td>1 (1.5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Malaysia</td>
<td>1 (1.5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Mexico</td>
<td>1 (1.5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Peru</td>
<td>1 (1.5)</td>
<td>1 (8.3)</td>
</tr>
<tr>
<td>Singapore</td>
<td>1 (1.5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>South Korea</td>
<td>1 (1.5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Turkey</td>
<td>1 (1.5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Venezuela</td>
<td>1 (1.5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Total</td>
<td>67 (100)</td>
<td>12 (100)</td>
</tr>
</tbody>
</table>
organ specific damage, which may further explain findings from histopathological and functional studies.

Although vivax malaria rarely develops hyperparasitemia, a hallmark of severe falciparum malaria, greater inflammatory and endothelial activation per parasite occurs in vivax malaria when compared with falciparum disease. Inflammatory exacerbation may cause pulmonary injury, whereas elevated cytokines and other inflammatory-inducing molecules may be responsible for alveolar-capillary barrier loss and increased permeability.134 Several reports from different Plasmodium species show that respiratory impairment begins several hours after antimalarials start, even in the presence of declining or negative parasitemia. In a falciparum malaria study, 79 patients developed respiratory failure, in the first 48 hours in 42% and afterward in 46%. Lung function studies revealed small airway obstructions and decreased diffusion capacity in both uncomplicated falciparum and vivax malaria.121,136,137 The capillary volume compartment in vivax patients was reduced at admission, returning to normal after treatment, whereas the membranous compartment was normal at presentation but progressively deteriorated. According to the authors, the uncoupling of both compartments at different time points is consistent with Plasmodium-infected red cells sequestration and a progressive alveolar-capillary injury due to a posttreatment inflammatory response to parasite killing.121 In vivax malaria, cytoadhesion of infected red cells to the endothelial cell layer is supported by recent studies. In an autopsy series, seven out of 13 patients in which vivax was the probable or contributing cause of death presented pulmonary complications.120 A lung tissue section from one of these patients presented images suggestive of sequestration of P. vivax-infected red cells within pulmonary vasculature. Interestingly, this sample was taken from a patient with negative peripheral parasitemia but with positive polymerase chain reaction for vivax in the lung.

The high number of patients needing mechanical ventilation and other advanced life-support strategies, which are not always available in resource-poor settings, may have impacted mortality. Early malaria diagnosis accompanied by effective antimalarial therapy, rapid identification of oxygen saturation deterioration with prompt support, and identification of complications could avoid progression to death.140

The time of oxygen support and length of hospitalization were lower among those who died, evidencing a more severe clinical deterioration than in survivors. Similarly, in a clinical characterization of vivax malaria patients suffering from ARDS and acute lung injury, older age, use of invasive mechanical ventilation, hypoxemia, presence of other organ involvement

<table>
<thead>
<tr>
<th>First author, year (reference)</th>
<th>Location</th>
<th>Study population</th>
<th>Total Severe ARDS Deaths ARDS /total ARDS /severe ARDS mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Studies with adult population</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kotwal, 200557</td>
<td>Afghanistan</td>
<td>American soldiers</td>
<td>38 1 1 0 2.6 100 0</td>
</tr>
<tr>
<td>Sharma, 200965</td>
<td>India</td>
<td>Records of malaria cases</td>
<td>221 – 3 3 1.3 100 0</td>
</tr>
<tr>
<td>Kochar, 200991</td>
<td>India</td>
<td>Patients admitted to hospital</td>
<td>456 40 4 2 0.8 100 50</td>
</tr>
<tr>
<td>George, 201071</td>
<td>India</td>
<td>Severe Pv admissions</td>
<td>30 30 1 1 3.3 3.3 100</td>
</tr>
<tr>
<td>Nayak, 201162</td>
<td>India</td>
<td>Severe malaria cases</td>
<td>80 80 4 4 5 5 100</td>
</tr>
<tr>
<td>Srivastava, 201163</td>
<td>India</td>
<td>Patient hospital presentations</td>
<td>50 41 3 0 6 7.3 0</td>
</tr>
<tr>
<td>Limaye, 201254</td>
<td>India</td>
<td>Patients admitted to hospital</td>
<td>336 50 10 6 2.9 20 60</td>
</tr>
<tr>
<td>Mehrmood, 201256</td>
<td>Pakistan</td>
<td>Pv cases in Emergency Dept.</td>
<td>97 – 1 0 1 – 0</td>
</tr>
<tr>
<td>Singh, 201366</td>
<td>India</td>
<td>Patients admitted to hospital</td>
<td>140 63 3 2 2.1 4.7 66.7</td>
</tr>
<tr>
<td>Rizvi, 201471</td>
<td>India</td>
<td>Patients admitted to hospital</td>
<td>172 62 6 2 3.5 9.7 33.3</td>
</tr>
<tr>
<td>Muley, 201470</td>
<td>India</td>
<td>Hospital admissions</td>
<td>100 – 6 1 6 – 16.6</td>
</tr>
<tr>
<td>Siqueira, 201571</td>
<td>Brazil</td>
<td>Patients admitted to hospital</td>
<td>316 40 7 1 22.2 17.5 14.2</td>
</tr>
<tr>
<td>Siqueira, 201571</td>
<td>India</td>
<td>Patients admitted to hospital</td>
<td>462 157 5 5 1.1 3.1 100</td>
</tr>
<tr>
<td>Jain, 201671</td>
<td>India</td>
<td>Patients in Emergency Dept.</td>
<td>48 25 2 1 4.1 8 50</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>2548 589 56 28 2.2 9.5 50</td>
</tr>
</tbody>
</table>
and comorbidities were considered risk factors for mortality. The higher presence of comorbidities found among non-survivors, along with higher presentation to hospital with respiratory impairment, probably explain the outcome in this group.

The pathogenesis of respiratory complications is historically better characterized in *P. falciparum* infection with studies revealing important lung vascular alterations: congested capillaries, thickened alveolar septum, diffuse edema, and hyaline membrane formation; endothelial cell swelling with narrowed capillary lumen, macrophages within interstitium and hemozoin; and presence of inflammatory and *Plasmodium*-infected red cells within capillaries. Essentially, and despite the progression and outcome of lung deterioration, the major difference between *P. falciparum* and *P. vivax* ARDS pathogenesis is the presence of more sequestration of parasitized red blood cells in the former and scanty evidence in the second.

Only studies containing respiratory complications were included, which may increase the prevalence estimates of respiratory complications. Furthermore, severe cases are more likely to be published, leading to a clear bias of publication. Also, calculations of disease prevalence or clinical outcome among several studies published with different objectives and lack of standardization on data reporting were expected limitations. The publications’ time range, different localities, and different case definitions may have affected, therefore, disease management and data reporting priorities, which may further have influenced the results of the present study. This lack of systematic reporting hampers broad data analysis and completeness.

**CONCLUSIONS**

To our knowledge, this is the first systematic review and meta-analysis attempting to estimate the frequency of...
respiratory complications in different vivax malaria populations, its disease characteristics, factors associated with death, and histopathology. As in falciparum malaria, vivax disease also presents an important rate of respiratory impairment among severe cases, with elevated mortality among children and adults. Female sex, presence of comorbidities, respiratory status at hospital admission, and lower hemoglobin values were found to statistically differ between survivors and non-survivors. Multicenter studies are needed using standardized protocols with adequate data registering, confirmation of mono-infections through molecular methodologies, exclusion of comorbidities, and other concurrent infections to better characterize vivax clinical spectrum and, specifically, respiratory impairment.

Received February 19, 2017. Accepted for publication April 19, 2017. Published online June 12, 2017.


Financial support: This work was funded by the National Counsel of Technological and Scientific Development [Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)]; the Amazonas Research Foundation [Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM)]; and The Fogarty International Center Global Health Fellowship [R25TW009337].

Disclaimer: Data included in this study were not previously presented or published elsewhere.

Authors’ addresses: Fernando Val, Kim Machado, Maria Graças Costa Alicerim, and Wuelton José Cassiano Neto, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil; and Universidade do Estado do Amazonas, Manaus, Brazil, E-mail: ffval@gmail.com, kim.machado01@gmail.com, gaecrim@fmt.am.gov.br, and wuellesmn@gmail.com. Lisiane Barbosa, Universidade do Estado do Amazonas, Manaus, Brazil, E-mail: lisianernesia@gmail.com. Jorge Luis Salinas, Emory University School of Medicine, Atlanta, GA, E-mail: jsalinas@emory.edu. André Machado Siqueira, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, E-mail: amssiqueira@gmail.com. Hernando del Portillo, Barcelona Institute for Global Health (ISGlobal) and ICREA, and Instituto d’Investigació Germans Trias i Pujol (IGTP), Badalona, Barcelona, Spain, E-mail: hernandodelportillo@isglobal.org. Quique Bassat, Barcelona Institute for Global Health (ISGlobal) and ICREA, Badalona, Spain, E-mail: quique.bassat@isglobal.org. Marcus Vinicius Guimarães Lacerda, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil, E-mail: marcus.lacerda.br@gmail.com.

REFERENCES


